Abstract
Neutropenia is increasingly common in the hospital. The rise in incidence is due to proliferation of indications for and centers performing hematopoietic stem cell transplantation, hematologic effects of AIDS, and myelosuppressive side-effects of anti-viral and cancer chemotherapies [Table 1]. As a result, these neutropenic patients are increasingly common in ICUs. These patients are often lymphopenic, anemic, and thrombocytopenic. They are at risk for multiple organ failures and various infections. This chapter will focus on respiratory infections in the neutropenic patient.
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Hathorn JW, Lyke K. Empirical treatment of febrile neutropenia: evolution of current therapeutic approaches. Clin Infect Dis 24(Suppl 2): S256, 1997.
Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323, 1993.
Rubin RH, Ferraro MJ. Understanding and diagnosing infectious complications in the immunocompromised host. Current issues and trends. Hematol Oncol Clin North Am 7:795, 1993.
Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 19:143, 1997.
Hubel K, Hegener K, Schnell R, et al. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. Ann Hematol 78:73, 1999.
Funada H, Matsuda T. Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period. Intern Med 37:1014, 1998.
Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al. The renal transplant patient with fever and pulmonary infiltrates: Etiology, clinical manifestations, and management. Medicine 59:206, 1980.
Rubin RH, Greene R. Clinical approach to the compromised host with fever and pulmonary infiltrates. In Rubin RH, Young LS (eds). Clinical Approach to Infection in the Compromised Host, 3rd edn. New York: Plenum Press, 1994: 121.
Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 7:771, 1993.
Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 18:25, 1994.
Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845, 1992.
Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 41:S7, 1998.
Sugar AM. Empiric treatment of fungal infections in the neutropenic host: review of the literature and guidelines for use. Arch Intern Med 150:2258, 1990.
Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:239, 1999.
Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 33:217, 1999.
Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 160:976, 1999.
Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15:414, 1992.
Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104:238, 1998.
Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine 1993.
Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325, 1994.
Richardson SE, Bannatyne RM, Summerbell RC, et al. Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis 10: 1171, 1988.
Boutai EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood 90:999, 1997.
Krcmery V Jr, Kunova E, Jesenska Z, et al. Invasive mold infections in cancer patients: Five years’ experience with Aspergillus,Mucor, Fusarium and Acremonium infections. Support Care Cancer 4:39, 1996.
Martino P, Gastaldi R, Raccah R, et al. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 28:7, 1994.
Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin Infect Dis 26:1383, 1996.
Kaiser L, Huguenin T, Lew PD, Chapuis B, Pittet D. Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine 77:188, 1998.
Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich JM, Raad II, Lewis V, Mirza N, Luna MA, Baxter B, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 21:376, 1995.
Won HJ, et al. Invasive pulmonary aspegillosis: Prediction at thin-section CT in patients with neutropenia — A prospective study. Radiology 208:777, 1998.
Jamzen DL, Adler BD, Padley SPG, et al. Diagnostic success of bronchoscopic biopsy in immunocompromised patients with acute pulmonary disease: Predictive value of disease distribution as shown on CT. Am J Roentgenol 160:21, 1993.
Scott WW, Kuhlman JE. Focal pulmonary lesions in patients with AIDS: Percutaneous transthoracic needle biopsy. Radiology 180:419, 1991.
Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552, 1986.
Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antim-crobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell’ Adulto Infection Program. Antimicrob Agents Chemother 40:1108, 1996.
Lindblad R, Rodjeer S, Adriansson M, et al. Empiric monotherapy for febrile neutropenia — A randomized study comparing meropenem with ceftazidime. Scand J Infect Dis 30:237, 1998.
Marie JP, et al. Neutropenic infections: Review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. J Antimicrob Chemo 4l(Suppl D):57, 1998.
Dompeling EC, Donnelly JP, Deresinski SC, et al. Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin. Eur J Cancer 32:1332, 1996.
Kibbler CC. Empirical antifungal therapy in febrile neutropenic patients: Current status. Current Topics in Medical Mycology 8:5, 1997.
Rotstein C, Bow EJ, Laverdiere M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: Benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 28:331, 1999.
Malik IA, Moid I, Aziz Z, et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 105:478, 1998.
Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122, 1997.
Einsele H, Hebart H, Roller G, Loffler J, Rothenhofer I, Muller CA, Bowden RA, van Burik J, Engelhard D, Kanz L, Schumacher U. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 35:1353, 1997.
Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764, 1999.
Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121:492, 1994.
Rowe JM. Treatment of acute myeloid leukemia with cytokines: Effects on duration of neutropenia and response to infections. Clin Infect Dis 26:1290, 1998.
Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed? Clin Infect Dis 26:1270, 1998.
Hughes WT, Armstrong D, Bodey GP, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 25:551, 1997.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Crawford, S.W. (2001). Respiratory Infection in Immunocompromised Neutropenic Patients. In: Rello, J., Valles, J., Kollef, M.H. (eds) Critical Care Infectious Diseases Textbook. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1679-8_41
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1679-8_41
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5674-5
Online ISBN: 978-1-4615-1679-8
eBook Packages: Springer Book Archive